Received July 17, 2013; Revision received August 29, 2013
Olovnikova et al. (“Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties” (2012) Biochemistry (Moscow), 77, 925-933) mentioned the presence of “alien sugars” on monoclonal antibodies (mAbs) produced by YB2/0 cell line. We summarize in this paper our previous findings on the glycosylation profile of two anti-D mAbs produced in this cell line (LFB-R297 and LFB-R593, so-called Roledumab). Our results show the absence of any immunogenic glycotopes, and furthermore neither immunogenicity nor other serious adverse reactions were observed during clinical trials.
KEY WORDS: YB2/0, monoclonal antibodies, anti-D, glycosylation, immunogenicity